摘要
目的评价盐酸凯普拉生片用于反流性食管炎(RE)患者治疗的经济性。方法以RE患者为研究对象,基于医保支付方角度,构建Markov模型模拟患者单次病程的健康效用和直接医疗费用,并使用成本-效果分析法比较凯普拉生方案和伏诺拉生方案的增量成本-效果比,从而评价盐酸凯普拉生片的经济优势,并进行敏感性分析来验证结果的稳定性。结果凯普拉生治疗方案的总成本为2225.40元,总质量调整生命年(QALYs)为1.08281;伏诺拉生治疗方案的总成本为2340.78元,总QALYs为1.08240;凯普拉生方案相比伏诺拉生治疗方案增量成本-效果比(ICER)为-280500.50元/QALY。敏感性分析中各因素对研究结论无明显影响。结论在对RE患者的治疗中,凯普拉生治疗方案与伏诺拉生治疗方案相比具有绝对优势。
Objective To evaluate the effectiveness and economy of kenuolazan hydrochloride tablets in the treatment of patients with reflux esophagitis(RE).Methods Using RE patients as the research subjects,from the perspective of medical insurance payer,we construct a Markov model to simulate the health utility and direct medical costs under each reference regimen,evaluating the economy of kenuolazan regimen compared to vonoprazan regimen in the treatment of reflux esophagitis based on the Incremental Cost-effectiveness Ratio(ICER),and sensitivity analysis was performed to verify the stability of the results.Results The total cost of the kenuolazan regimen was RMB 2 225.40 with total QALYs of 1.082 81,and the total cost of the vonoprazan regimen was RMB 2 340.78 with total QALYs of 1.082 40.The ICER was-280 500.50 RMB/QALY.The factors in the sensitivity analysis had no significant impact on the study findings.Conclusion In the treatment of RE patients,the kenuolazan regimen has a clear advantage over the vonoprazan regimen.
作者
程莉丽
陈卓
李自刚
陈鑫
曹珲
CHENG Li-Li;CHEN Zhuo;LI Zi-Gang;CHEN Xin;CAO Hui(Jiangsu Medical Insurance Research Institute,Medical Insurance Medical Device Professional Committee,Nanjing 210015,China;Fosun Pharmaceutical(domestic marketing platform),Shanghai 200233,China;Jiangsu Kefiping Pharmaceutical Co.,LTD,Nanjing 210015,China)
出处
《中国药物经济学》
2024年第7期5-11,15,共8页
China Journal of Pharmaceutical Economics
